SZN-043 is under clinical development by Surrozen and currently in Phase I for Alcoholic Hepatitis. According to GlobalData, Phase I drugs for Alcoholic Hepatitis does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the SZN-043 LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SZN-043 overview

SZN-043 is under development for the treatment of severe liver diseases such as severe alcoholic hepatitis. SZN-043 is a hepatocyte-specific R-spondin mimetic bi-specific fusion protein developed based on SWEETS (Surrozen Wnt signal Enhancers Engineered for Tissue Specificity) platform technology. It acts by targeting E3 ubiquitin ligase and Asialoglycoprotein receptor 1 (ASGR1) in wnt pathway.

Surrozen overview

Surrozen a clinical stage biotechnology company that focused on discovering and developing protein therapeutics to promotes repair and regeneration of human tissues. It is headquartered in San Francisco, California, the US.

For a complete picture of SZN-043’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.